Explain this page
Arphra AIPlain-English read on ANI Pharmaceuticals, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1,307.26
+1544.56% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
8bull6bear
±5% threshold
Analyst PT consensus: $124.00 (+55.99%)
Candlestick · 1Y
Open in chart workstation →ANIP
79.49-0.64%H 87.76L 70.15MA50 77.86MA200 —Avg vol 379K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.28% | -3.18% | -1.03% | +6.24% | -4.06% | +0.70% | +21.25% | +50.92% | +136.44% | +49.73% | -62.81% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$4.76M
6 txns
Net flow
−$4.76M
Aftermarket
LiveLast trade
$78.52
4 sh
Bid
$78.19
4 sh
Ask
$85.00
4 sh
Spread
$6.810
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $247.06M | $27.49M | $1.17 |
| Q3 Sep 2025 | $227.81M | $24.13M | $1.13 |
| Q2 Jun 2025 | $211.37M | $8.55M | $0.36 |
| Q1 Mar 2025 | $197.12M | $15.68M | $0.69 |
| Q4 Dec 2024 | $190.57M | -$10.28M | $-0.55 |
| Q3 Sep 2024 | $148.33M | -$24.17M | $-1.27 |
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Consumer Defensive-0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.99%
- Healthcare-1.51%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - Specialty & Generic-1.01%
- Oil & Gas Energy+8.53%
- Business Equipment & Supplies+5.82%
- Semiconductors+5.24%
- Electronic Gaming & Multimedia+5.23%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Financial - Mortgages+4.08%
- Broadcasting+4.00%
- Computer Hardware-3.67%
- Internet Content & Information+3.58%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stockzacks.com·Jun 16, 2026
- Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?zacks.com·Jun 10, 2026
- ANI Pharmaceuticals Targets Acute Gout With Cortrophin Pushzacks.com·Jun 10, 2026
- ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growthzacks.com·Jun 10, 2026
- ANI Pharmaceuticals Q1 Earnings Call Highlightsmarketbeat.com·May 08, 2026
- ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidanceglobenewswire.com·May 08, 2026
- Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?zacks.com·May 04, 2026
- ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?zacks.com·May 01, 2026
Peers
No peer list available for ANIP.
Total assets
$1.44B
Total debt
$325.2M
Cash & equiv
$285.59M
Operating CF
$185.23M
Free cash flow
$171.39M
Buybacks
-$12.21M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Cook Meredith officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $41.02K | Jun 12, 2026 |
HAUGHEY THOMAS director | Sell | 2,000 | $161.76K | Jun 08, 2026 |
Cook Meredith officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $39.08K | May 13, 2026 |
Rowland Thomas Andrew officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $36.36K | May 12, 2026 |
Gutwerg Ori officer: SVP, GENERICS | Sell | 2,772 | $220.37K | May 12, 2026 |
Lalwani Nikhil director, officer: PRESIDENT & CEO | Sell | 55,000 | $4.27M | May 11, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $883.37M | $81.23M | $78.34M | $3.32 | +8.87% |
| FY 2024 | $614.38M | $584K | -$18.52M | $-1.04 | -3.01% |
| FY 2023 | $486.82M | $46.97M | $18.78M | $0.94 | +3.86% |
| FY 2022 | $316.39M | -$35.28M | -$47.9M | $-3.05 | -15.14% |
| FY 2021 | $216.14M | -$39.79M | -$42.6M | $-3.40 | -19.71% |